IHRT

IHRT is not a cheap stock so much as a leveraged option on a shrinking business. The headline P/S of 0.2 is an illusion created by the tiny $676M market cap sitting on top of $4.98B of long-term debt (plus $73.4M current), so enterprise value is roughly $5.6B against ~$3.86B of revenue and only $92.6M of operating cash flow. Stockholders' equity is deeply negative at -$1.83B with a -$4.81B accumulated deficit — the balance sheet is upside-down, and equity holders are last in line behind that debt stack. FY2025 operating cash flow barely covers the $81.7M of capex, leaving almost no free cash flow to service, let alone reduce, the debt.

The operating business is stagnant and structurally challenged. Revenue has been flat for five years ($3.56B→$3.86B, +0.3% YoY in FY2025), and the company has lost money every single year 2021–2025, with two ~$1B loss years (2023–2024) driven by the impairments management flags in its risk factors. The FY2025 net loss of -$473M and near-breakeven operating income (-$20.6M) are an improvement, but 'less bad' on a still-negative line is not a turnaround — operating margin is -0.5% and net margin -12.2%. Management's own MD&A leans on the boilerplate that liquidity is sufficient 'for at least the next twelve months,' which underscores how tight the runway is.